Ionis Pharmaceuticals (IONS) Competitors $70.86 -0.64 (-0.90%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$70.92 +0.06 (+0.08%) As of 10/24/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IONS vs. BIIB, UTHR, INCY, NBIX, EXAS, EXEL, BMRN, MDGL, RGEN, and HALOShould you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Repligen (RGEN), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Ionis Pharmaceuticals vs. Its Competitors Biogen United Therapeutics Incyte Neurocrine Biosciences Exact Sciences Exelixis BioMarin Pharmaceutical Madrigal Pharmaceuticals Repligen Halozyme Therapeutics Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk. Do analysts rate BIIB or IONS? Biogen presently has a consensus target price of $180.69, suggesting a potential upside of 20.55%. Ionis Pharmaceuticals has a consensus target price of $78.50, suggesting a potential upside of 10.78%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Ionis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 20 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.35Ionis Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has more risk and volatility, BIIB or IONS? Biogen has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Does the media refer more to BIIB or IONS? In the previous week, Biogen had 40 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 45 mentions for Biogen and 5 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.37 beat Biogen's score of 1.04 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 23 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Ionis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in BIIB or IONS? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 2.6% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is BIIB or IONS more profitable? Biogen has a net margin of 15.31% compared to Ionis Pharmaceuticals' net margin of -28.25%. Biogen's return on equity of 13.85% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Ionis Pharmaceuticals -28.25%-45.29%-8.99% Which has preferable valuation & earnings, BIIB or IONS? Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$10.00B2.20$1.63B$10.4614.33Ionis Pharmaceuticals$705M16.02-$453.90M-$1.84-38.51 SummaryBiogen beats Ionis Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IONS vs. The Competition Export to ExcelMetricIonis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.40B$2.97B$6.23B$10.66BDividend YieldN/A57.75%5.71%4.82%P/E Ratio-38.5125.2430.2030.21Price / Sales16.02782.34590.34132.63Price / CashN/A168.3237.0161.44Price / Book19.005.6512.046.60Net Income-$453.90M$33.06M$3.32B$276.82M7 Day Performance-3.05%3.15%1.89%2.58%1 Month Performance12.53%8.13%7.68%3.76%1 Year Performance80.81%-2.49%56.01%33.84% Ionis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IONSIonis Pharmaceuticals3.4994 of 5 stars$70.86-0.9%$78.50+10.8%+82.8%$11.40B$705M-38.511,069Upcoming EarningsBIIBBiogen4.7197 of 5 stars$144.69-1.3%$180.15+24.5%-18.5%$21.49B$9.68B9.157,605Trending NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionUTHRUnited Therapeutics4.8441 of 5 stars$440.06+0.0%$457.21+3.9%+19.5%$19.85B$2.88B17.171,305Positive NewsUpcoming EarningsAnalyst ForecastInsider TradeINCYIncyte4.5535 of 5 stars$84.73+1.1%$84.79+0.1%+39.9%$16.36B$4.24B20.852,617Upcoming EarningsNBIXNeurocrine Biosciences4.3993 of 5 stars$137.35+0.5%$163.44+19.0%+24.7%$13.55B$2.36B40.421,800Upcoming EarningsAnalyst ForecastEXASExact Sciences4.5142 of 5 stars$59.36+1.7%$69.19+16.6%-8.0%$11.04B$2.76B0.007,000Analyst ForecastEXELExelixis4.7601 of 5 stars$38.44+0.8%$44.42+15.6%+37.7%$10.27B$2.17B18.521,147Analyst UpgradeAnalyst RevisionBMRNBioMarin Pharmaceutical4.9722 of 5 stars$52.45+0.2%$93.26+77.8%-22.6%$10.05B$2.85B14.183,040News CoverageAnalyst ForecastMDGLMadrigal Pharmaceuticals4.8415 of 5 stars$427.73-0.4%$525.88+22.9%+107.6%$9.54B$180.13M0.0090Positive NewsRGENRepligen4.1887 of 5 stars$148.67+2.4%$169.62+14.1%+23.0%$8.17B$634.44M89.101,778HALOHalozyme Therapeutics4.857 of 5 stars$65.33+1.9%$70.44+7.8%+34.2%$7.50B$1.02B13.19390Analyst Forecast Related Companies and Tools Related Companies BIIB Competitors UTHR Competitors INCY Competitors NBIX Competitors EXAS Competitors EXEL Competitors BMRN Competitors MDGL Competitors RGEN Competitors HALO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IONS) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
